Fed. Circ. Won't Toss Mylan's Appeal Of Epilepsy Drug Patent
The Federal Circuit refused Thursday to toss Mylan's appeal challenging the Patent Trial and Appeal Board's decision to validate a patent for brand-name epilepsy drug Vimpat, rejecting arguments that Mylan can't...To view the full article, register now.
Already a subscriber? Click here to view full article